CERo Therapeutics Holdings Inc
CEROW0.004USD
0.000
Close 12/24, 16:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of CERo Therapeutics Holdings Inc Company
CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. The Company’s proprietary approach to T cell engineering, enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, which is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. Its cellular immunotherapy platform is focused on redirecting patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating CERo, which is referred to as chimeric engulfment receptor t cells (CER-T). The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.
CERo Therapeutics Holdings Inc Info
Ticker SymbolCEROW
Company nameCERo Therapeutics Holdings Inc
IPO dateOct 06, 2021
CEOMr. Christopher B. (Chris) Ehrlich
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address201 Haskins Way
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94080
Phone6504072376
Websitehttps://www.phoenixbiotechacquisitioncorp.com/
Ticker SymbolCEROW
IPO dateOct 06, 2021
CEOMr. Christopher B. (Chris) Ehrlich
Company Executives of CERo Therapeutics Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
--
--
Dr. Lindsey Rolfe
Dr. Lindsey Rolfe
Independent Director
Independent Director
--
--
Mr. Christopher B. (Chris) Ehrlich
Mr. Christopher B. (Chris) Ehrlich
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Andrew (Al Kucharchuk) Albert
Mr. Andrew (Al Kucharchuk) Albert
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Kristen Pierce
Dr. Kristen Pierce
Chief Development Officer
Chief Development Officer
--
--
Mr. Brian G. Atwood
Mr. Brian G. Atwood
Director
Director
--
--
Mr. Shami J. Patel
Mr. Shami J. Patel
Director
Director
--
--
Mr. Michael (Mike) Byrnes
Mr. Michael (Mike) Byrnes
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
--
--
Dr. Lindsey Rolfe
Dr. Lindsey Rolfe
Independent Director
Independent Director
--
--
Mr. Christopher B. (Chris) Ehrlich
Mr. Christopher B. (Chris) Ehrlich
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Andrew (Al Kucharchuk) Albert
Mr. Andrew (Al Kucharchuk) Albert
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Kristen Pierce
Dr. Kristen Pierce
Chief Development Officer
Chief Development Officer
--
--
Mr. Brian G. Atwood
Mr. Brian G. Atwood
Director
Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
60
3.66M
0.00%
-2.89M
2025Q2
59
3.77M
0.00%
-2.93M
2025Q1
62
3.79M
0.00%
-3.02M
2024Q4
64
3.89M
0.00%
-3.70M
2024Q3
74
5.64M
0.00%
-2.20M
2024Q2
75
5.72M
0.00%
-2.19M
2024Q1
75
5.78M
0.00%
-1.21M
2023Q4
70
5.74M
0.00%
-1.39M
2023Q3
69
6.16M
0.00%
-715.27K
2023Q2
69
6.14M
0.00%
-952.62K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Wolverine Asset Management, LLC
33.80K
0%
-10.00K
-22.83%
Jun 30, 2025
Voya Investments, LLC
21.94K
0%
--
--
Jul 31, 2025
Whitebox Advisors, L.L.C.
23.25K
0%
--
--
Jun 30, 2025
Atalaya Capital Management LP
424.87K
0%
-133.00
-0.03%
Jun 30, 2024
MMCAP Asset Management
375.00K
0%
--
--
Jun 30, 2025
Saba Capital Management, L.P.
295.91K
0%
--
--
Jun 30, 2025
Clear Street Derivatives LLC
268.13K
0%
--
--
Jun 30, 2025
Linden Advisors L.P.
250.00K
0%
--
--
Jun 30, 2025
Blue Owl Capital Holdings LP
224.93K
0%
--
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of CERo Therapeutics Holdings Inc?
The top five shareholders of CERo Therapeutics Holdings Inc are:
Wolverine Asset Management, LLC holds 33.80K shares, accounting for 0.00% of the total shares.
Voya Investments, LLC holds 21.94K shares, accounting for 0.00% of the total shares.
Whitebox Advisors, L.L.C. holds 23.25K shares, accounting for 0.00% of the total shares.
Atalaya Capital Management LP holds 424.87K shares, accounting for 0.00% of the total shares.
MMCAP Asset Management holds 375.00K shares, accounting for 0.00% of the total shares.
Wolverine Asset Management, LLC holds 33.80K shares, accounting for 0.00% of the total shares.
Voya Investments, LLC holds 21.94K shares, accounting for 0.00% of the total shares.
Whitebox Advisors, L.L.C. holds 23.25K shares, accounting for 0.00% of the total shares.
Atalaya Capital Management LP holds 424.87K shares, accounting for 0.00% of the total shares.
MMCAP Asset Management holds 375.00K shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of CERo Therapeutics Holdings Inc?
The top three shareholder types of CERo Therapeutics Holdings Inc are:
Other
Other
How many institutions hold shares of CERo Therapeutics Holdings Inc (CEROW)?
As of 2025Q3, 60 institutions hold shares of CERo Therapeutics Holdings Inc, with a combined market value of approximately 3.66M, accounting for --% of the total shares. Compared to 2025Q2, institutional shareholding has increased by --.
What is the biggest source of revenue for CERo Therapeutics Holdings Inc?
In --, the -- business generated the highest revenue for CERo Therapeutics Holdings Inc, amounting to -- and accounting for --% of total revenue.
